NEW YORK (GenomeWeb) –Axiogenesis today announced it has sublicensed patents from GE Healthcare to allow the German cell supplier to commercialize technologies based on human induced pluripotent stem cells (iPSCs).

Under the terms of the agreement, GE Healthcare will sublicense patents for the use of human iPSCs which will enable Axiogenesis to develop cellular assays and stem cell-derived models of disease for use in drug discovery and toxicity screening.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.

Fortune reports that a Philadelphia-area hospital system is offering its employees free genetic testing.